Cambridge Newswire

Comprehensive Real-Time News Feed for Cambridge, MA.

Results 1 - 20 of 90 for "u:bloomberg.com" in Cambridge, MA

  1. Harvard Endowment's Blyth Resigns From $37.6 Billion FundRead the original story

    4 hrs ago | The Washington Post

    Stephen Blyth, who was named the investing chief of Harvard University's $37.6 billion endowment 18 months ago to improve the fund's lackluster performance, resigned for personal reasons, the university said. Blyth, 48, who has been on an unspecified temporary medical leave since May 23, departs immediately, Harvard Management Co., the school's investment management arm, said in a statement Wednesday.

    Comment?

  2. Akamai Plunges After Earnings, Sales Forecast Miss EstimatesRead the original story

    8 hrs ago | The Washington Post

    Akamai Technologies, Inc. plunged as much as 13 percent in early trading Wednesday after forecasting earnings and sales in the current quarter that fell short of analysts' estimates. The Cambridge, Massachusetts-based company, whose technology helps speed delivery of internet content said its biggest technology customers, like Apple Inc. and Facebook Inc., are turning to a do-it-yourself model and are increasingly capable of moving more data through their own systems.

    Comment?

  3. Biogen's CEO Is Out After Management Changes, Stalled SalesRead the original story

    Thursday Jul 21 | The Washington Post

    Biogen Inc. Chief Executive Officer George Scangos, who helped build the U.S. drugmaker into a powerful player in multiple sclerosis treatments, will leave the company after a series of top managers were replaced and sales of its biggest product stalled. Scangos, 68, will stay on until a replacement is found, Biogen said in a statement Thursday in which it also reported second-quarter earnings.

    Comment?

  4. Biogen CEO Scangos to Depart as Drugmaker Raises GuidanceRead the original story

    Thursday Jul 21 | The Washington Post

    Biogen Inc.'s Chief Executive Officer George Scangos will leave the company "in the coming months," the drugmaker said as it reported that second-quarter profit topped analysts' estimates. The company will begin searching for a successor to Scangos immediately and he will continue as CEO until a replacement is found, Biogen said in a statement Thursday.

    Comment?

  5. Energy Veteran Betting on LNG Bounce Sees Future Floating at SeaRead the original story

    Tuesday Jul 19 | The Washington Post

    Turmoil in the oil market gave Fred Jones his start in the energy business four decades ago. Now he'll be hoping turmoil in the gas market doesn't sour his new venture.

    Comment?

  6. Energy Veteran Betting on LNG Bounce Sees Future Floating at SeaRead the original story

    Monday Jul 18 | The Washington Post

    Turmoil in the oil market gave Fred Jones his start in the energy business four decades ago. Now he'll be hoping turmoil in the gas market doesn't sour his new venture.

    Comment?

  7. Buffett-Backed Abortion Researchers Messed With Texas and WonRead the original story w/Photo

    Friday Jul 1 | Bloomberg

    Behind the U.S. Supreme Court's historic abortion ruling this week was a small band of academic researchers whose trove of data and analysis was instrumental in dismantling some of the country's toughest restrictions on the procedure in Texas and beyond. The Texas Policy Evaluation Project, known as TxPEP, assigned five researchers to traverse the state to gather statistics from abortion providers, amass public records and interview women.

    Comment?

  8. Gates Says Altered Mosquitoes Are Next Weapon in Malaria FightRead the original story w/Photo

    Jun 16, 2016 | Bloomberg

    In recent years, biologists armed with a new gene-editing technology have proposed altering mosquitoes so they're more resistant to diseases like malaria and dengue. Using a mechanism known as a " "In less in five years, I think there's a good chance it will be out there," Gates said in an interview with Bloomberg News before speaking at a conference of the American Society for Microbiology in Boston.

    Comment?

  9. Energy World's Newest Supership Misses the Boat on LNG PricingRead the original story

    Jun 12, 2016 | The Washington Post

    It's longer than three soccer fields, heavier than two aircraft carriers and powerful enough to chill gas into liquid colder than the surface of Jupiter. The world's first modern vessel for producing liquefied natural gas was ordered by Petroliam Nasional Bhd in 2012 when LNG traded for more than $15 per million British thermal units.

    Comment?

  10. Novartis Cements China Plans as $1 Billion Research Center OpensRead the original story

    Jun 1, 2016 | The Washington Post

    The seven-building campus on the outskirts of Shanghai is accented by bamboo staircases and tree-lined courtyards. The company said the 1,300-person facility will be its third major research center, after Basel, Switzerland, and Cambridge, Massachusetts.

    Comment?

  11. Novartis Cements China Plans as $1 Billion Research Center OpensRead the original story

    Jun 1, 2016 | The Washington Post

    The seven-building campus on the outskirts of Shanghai is accented by bamboo staircases and tree-lined courtyards. The company said the 1,300-person facility will be its third major research center, after Basel, Switzerland, and Cambridge, Massachusetts.

    Comment?

  12. Funds Step Back From Gold Before Yellen Says Rate Rise Is ComingRead the original story

    May 30, 2016 | The Washington Post

    Hedge funds decided to take a breather from gold just before Janet Yellen gave investors more reason to ditch the precious metal. After a roaring start to the year, the excitement over bullion has dissipated this month on increasing expectations that the Federal Reserve is getting ready to raise U.S. interest rates again as the economy improves.

    Comment?

  13. Yellen Leans Toward Near-Term Rate Rise Without Detailing Timing 16 minutes agoRead the original story

    May 27, 2016 | Bloomberg

    Federal Reserve Chair Janet Yellen threw her support behind a growing consensus at the central bank in favor of another interest rate increase soon, while steering clear of specifying the timing of such a move. "It's appropriate -- and I've said this in the past -- for the Fed to gradually and cautiously increase our overnight interest rate over time," Yellen said Friday during remarks at Harvard University in Cambridge, Massachusetts.

    Comment?

  14. Yellen Says Fed Hike Probably Appropriate in - Coming Months' 27 minutes agoRead the original story

    May 27, 2016 | Bloomberg

    Federal Reserve Chair Janet Yellen said the ongoing improvement in the U.S. economy would warrant another interest rate increase "in the coming months," stopping short of giving an explicit hint that the central bank would act in June. "It's appropriate -- and I've said this in the past -- for the Fed to gradually and cautiously increase our overnight interest rate over time," Yellen said Friday during remarks at Harvard University in Cambridge, Massachusetts.

    Comment?

  15. Carlyle's Rubenstein to Join Harvard Board of TrusteesRead the original story

    May 26, 2016 | The Washington Post

    David Rubenstein, co-chief executive officer of alternative-asset manager Carlyle Group LP, will join Harvard University's board of trustees in July 2017. Rubenstein, 66, will replace Nannerl Keohane, former president of Duke University and Wellesley College, when she steps down next year from the board known as Harvard Corp., the Cambridge, Massachusetts-based school said Wednesday in a statement.

    Comment?

  16. Alnylam Soars as Drugmakers Circle Rival Biotechnology CompanyRead the original story

    May 26, 2016 | The Washington Post

    Alnylam Pharmaceuticals Inc. rose as much as 12 percent, the most in more than a year, after Sanofi, which owns a stake in the company, accelerated its pursuit of another drugmaker as potential rivals circled, suggesting demand for biotechnology acquisitions may be picking up. Sanofi Chief Executive Officer Olivier Brandicourt proposed eight independent candidates to replace Medivation Inc.'s board after the sitting members spurned the French company's takeover offer.

    Comment?

  17. Sarepta Surges After FDA Delays Ruling on DMD DrugRead the original story

    May 26, 2016 | The Washington Post

    Sarepta Therapeutics Inc. surged Wednesday after the biotechnology company said U.S. regulators delayed ruling on its drug for a deadly muscle disease, raising hopes that the therapy could be approved. The Food and Drug Administration notified Sarepta that it won't complete its review of the drug, known as eteplirsen, by the scheduled May 26 deadline, Sarepta said Wednesday in a statement.

    Comment?

  18. Desperate Patients, Impatient Investors Await Sarepta Drug CallRead the original story

    May 25, 2016 | The Washington Post

    Boys with a deadly muscle disease are anxiously awaiting a decision this week from U.S. regulators on a new treatment from Sarepta Therapeutics Inc., a verdict that may raise or dash the hopes of patients and decide the fate of the drugmaker. If the Food and Drug Administration rejects eteplirsen, Sarepta's experimental therapy for Duchenne muscular dystrophy, it will be the third drug that DMD patients have seen turned down by regulators this year.

    Comment?

  19. Sarepta Surges After U.S. Regulators Delay Ruling on DMD Drug 2 hours agoRead the original story

    May 25, 2016 | Bloomberg

    Sarepta Therapeutics Inc. surged in early trading after the biotechnology company said U.S. regulators had delayed ruling on its drug for a deadly muscle disease, raising hopes that the therapy could be approved. The Food and Drug Administration notified Sarepta that it won't complete its review of the drug, known as eteplirsen, by the scheduled May 26 deadline, Sarepta said Wednesday in a statement.

    Comment?

  20. Harvard Turns to Another Pimco Veteran With Ettl in Interim RoleRead the original story

    May 23, 2016 | The Washington Post

    The new temporary leader at Harvard University's endowment will bring a familiar background to the role -- experience in building the Pacific Investment Management Co. Robert Ettl, chief operating officer at Harvard Management Co., the $37.6 billion endowment's management arm, is the interim chief executive officer while Stephen Blyth is on medical leave, the Cambridge, Massachusetts-based school said in a statement Monday.

    Comment?

Cambridge Job Listings
View or post Cambridge job listings on Topix.
Cambridge Real Estate
News, listings, and foreclosures in Cambridge from Topix.
Cambridge Mortgages
Find mortgage rates in Cambridge on Topix.